|
Stooges guitarist Ron Asheton found dead
|
COL BKB: Clemson 66, Alabama 59
January 7, 2009 - 0 comments
|
| Cover Story |
In an interview with the Financial Times published over the weekend, Pfizer 's (NYSE: PFE) CEO Jeff Kindler said the company's willing to buy another company -- maybe big, maybe small. And no fewer than a dozen news articles jumped on the bandwagon (not including this one).Is this something that investors really need? Must be a really slow news day.
For months now, Kindler's been saying that he'd like to make the best investments possible for the company. For instance, last March, Kindler said, "Purchasing growth for us, it has to make sense both from a value and a risk perspective and we will evaluate the tradeoffs carefully, while staying opportunistic." And investors should expect nothing less. Whether the purchase is a relatively large company like Gilead Sciences (Nasdaq: GILD), Amgen (Nasdaq: AMGN), or even Wyeth (NYSE: WYE) or a series of smaller acquisitions like GlaxoSmithKline (NYSE: GSK) announced last year with its purchases of Sirtris Pharmaceuticals and Genelabs Technologies, Pfizer needs to keep return at the fore.
|
|
|
| |
My Money |
|
|
5-Star Stocks on the Upswing
Sadly, there's no such thing as an ultimate buy signal when it comes to investing in stocks. Identifying companies with the wind at their back takes time, patience, and a good dose of due diligence.
|
|
|
|
|
| |
|
|
|
